BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

After two years in stealth mode, Neuron23 has emerged with $113.5 million in two venture rounds that will support development of programs sourced from a German biotech against two targets implicated in...
BioCentury | Dec 13, 2019
Finance

Aspen’s debut reveals first cell therapy investment by Domain

Aspen emerged from stealth Thursday with an autologous stem cell therapy for Parkinson’s disease. The company’s 2018 $6.5 million seed round, led by Domain Associates and Axon Ventures, marked Domain’s first investment in cell therapy....
BioCentury | Apr 23, 2019
Translation in Brief

J&J and Boston University identify classifications to catch lung cancer

J&J and Boston University identified a subtype of precancerous lesions with genomic alterations and immune cell deficiencies that could be used to diagnose and stratify patients at the earliest stages of lung cancer. The findings,...
BioCentury | Dec 5, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers A panel of 11 genes could help predict response to inhaled corticosteroids in COPD patients. In 49 patients with COPD, high expression in airway epithelial samples of an 11-gene panel...
BioCentury | Jun 6, 2018
Translation in Brief

Distinguishing DLBCL

...that were defined by the combinations of different genetic alterations” such that the combinations constituted genetic signatures...
...subset, or cluster, of tumors were a mixture of the different classes of changes. The genetic signatures...
...will help develop and link more precise therapeutic strategies to DLBCL patient subsets with defined genetic signatures...
BioCentury | Sep 29, 2017
Financial News

Eligo raises $20M series A

On Sept. 26, microbiome company Eligo Bioscience S.A.S. (Paris, France) said it raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. CEO and Chairman...
BioCentury | Sep 26, 2017
Financial News

Eligo raises $20M series A

Microbiome company Eligo Bioscience S.A.S. (Paris, France) raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. The round included a $2 million award from...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...company uses its bioinformatics algorithms to interrogate the registry data. The goal is to define genetic signatures...
BioCentury | Oct 24, 2016
Product Development

A new BEAT for AML

With the first collaborative, multidrug trial in a blood cancer, The Leukemia & Lymphoma Society aims to dramatically alter the 40-year-old diagnosis and treatment paradigm in first-line acute myelogenous leukemia, and to create a virtuous...
BioCentury | Jul 14, 2016
Politics & Policy

RACE for Children Act would require pediatric cancer studies

...drugs. Cancers are still defined by their tissue of origin rather than by molecular or genetic signatures...
Items per page:
1 - 10 of 38
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

After two years in stealth mode, Neuron23 has emerged with $113.5 million in two venture rounds that will support development of programs sourced from a German biotech against two targets implicated in...
BioCentury | Dec 13, 2019
Finance

Aspen’s debut reveals first cell therapy investment by Domain

Aspen emerged from stealth Thursday with an autologous stem cell therapy for Parkinson’s disease. The company’s 2018 $6.5 million seed round, led by Domain Associates and Axon Ventures, marked Domain’s first investment in cell therapy....
BioCentury | Apr 23, 2019
Translation in Brief

J&J and Boston University identify classifications to catch lung cancer

J&J and Boston University identified a subtype of precancerous lesions with genomic alterations and immune cell deficiencies that could be used to diagnose and stratify patients at the earliest stages of lung cancer. The findings,...
BioCentury | Dec 5, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers A panel of 11 genes could help predict response to inhaled corticosteroids in COPD patients. In 49 patients with COPD, high expression in airway epithelial samples of an 11-gene panel...
BioCentury | Jun 6, 2018
Translation in Brief

Distinguishing DLBCL

...that were defined by the combinations of different genetic alterations” such that the combinations constituted genetic signatures...
...subset, or cluster, of tumors were a mixture of the different classes of changes. The genetic signatures...
...will help develop and link more precise therapeutic strategies to DLBCL patient subsets with defined genetic signatures...
BioCentury | Sep 29, 2017
Financial News

Eligo raises $20M series A

On Sept. 26, microbiome company Eligo Bioscience S.A.S. (Paris, France) said it raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. CEO and Chairman...
BioCentury | Sep 26, 2017
Financial News

Eligo raises $20M series A

Microbiome company Eligo Bioscience S.A.S. (Paris, France) raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. The round included a $2 million award from...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...company uses its bioinformatics algorithms to interrogate the registry data. The goal is to define genetic signatures...
BioCentury | Oct 24, 2016
Product Development

A new BEAT for AML

With the first collaborative, multidrug trial in a blood cancer, The Leukemia & Lymphoma Society aims to dramatically alter the 40-year-old diagnosis and treatment paradigm in first-line acute myelogenous leukemia, and to create a virtuous...
BioCentury | Jul 14, 2016
Politics & Policy

RACE for Children Act would require pediatric cancer studies

...drugs. Cancers are still defined by their tissue of origin rather than by molecular or genetic signatures...
Items per page:
1 - 10 of 38